Pila Pharma

PILA PHARMA CLARIFIES: DECISION TO POSTPONE THE ANNUAL REPORT TO AWAIT CONCLUSION ON PRECLINICAL OBESITY STUDIES

PILA PHARMA POSTPONES THE PUBLICATION OF THE ANNUAL REPORT AND THE ANNUAL GENERAL MEETING

PILA PHARMA: TO PARTICIPATE IN PHARMA PARTNERSHIP CONFERENCE BIO EUROPE SPRING IN LISBON, MARCH 23-25

PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE - CEO & FOUNDER'S PARTICIPATION DISCLOSED

PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS

PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2

PILA PHARMA: Upcoming last days for exercise with the warrants of series TO2

PILA PHARMA: CEO REPORT INTERVIEW AND Q&A ON CLINICAL PLANS, TO2 WARRANTS AND MORE, AVAILABLE FOR REPLAY NOW

PILA PHARMA: INVITATION TO LIVE H2 / YEAR-END REPORT INTERVIEW AND Q&A TODAY AT 14:00 CET

PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2025.

PILA PHARMA PREPARES CLINICAL TRIAL APPLICATION IN RARE DISEASE ERYTHROMELALGIA

PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announces that it has initiated preparations for a clinical trial application for a proof-of-concept study in the rare disease erythromelalgia.

THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY

PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, completed a rights issue of units during the third quarter of 2025 (the "Rights Issue"). One unit consisted of one (1) share and one (1) warrant of series TO2. Each warrant of series TO2 gives the owner right to subscribe for two (2) new shares in the Company. The exercise price for the warrants of series TO2 is to be determined to 70 per cent of the volume-weighted average price paid for the Company's share on Nasdaq First North Growth Market during the measurement period, the ten (10) trading days preceding 05 February 2026, however, not less than SEK 1.50 per share and not more than SEK 3.00 per share. During the measurement period, the volume-weighted average price (VWAP) in the Company's share was approximately SEK 1.45, therefore, the exercise price for the warrants of series TO2 has been determined to SEK 1.50. The exercise period for warrants of series TO2 commence today and runs up to and including 15 February 2026.